If a company's performance is determined by the abstracts they publish, there will be many winners. DNDN published a merit-award winning abstract on APC8024 last year. They are presenting one more abstract this year on APC8024. However, if you see the progress made on the actual product, there is not much. It is still in preparation for P-II trial and have been for a while. In fact, when DND went public, Provenge was in P-III stage trials and APC8024 was in P-I trials. I own DNDN stock and desperately want them to succeed. Presenting abtracts is nice but it does not really bring home the proverbial bacon.